Empowering People to be Ambassadors of their Own Health Since 1997.


Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on Lung Cancer
Literature Review, March 2015



Assessing the Effects of Concurrent vs. Sequential Cisplatin/Radiotherapy on Immune Status in Lung Tumor-Bearing C57BL/6 Mice. Kao CJ1, Wurz GT1, Lin YC2, et al. Cancer Immunol Res. 2015 Feb 11. pii: canimm.0234.2014. [Epub ahead of print]

Racial diversity of actionable mutations in non-small cell lung cancer. Bollig-Fischer A1, Chen W, Gadgeel SM, Wenzlaff AS, Cote ML, Schwartz AG, Bepler G. J Thorac Oncol. 2015 Feb;10(2):250-5. doi: 10.1097/JTO.0000000000000420.

Transcriptome Analysis of Individual Stromal Cell Populations Identifies Stroma-Tumor Crosstalk in Mouse Lung Cancer Model. Choi H1, Sheng J2, Gao D3, et al. Cell Rep. 2015 Feb 17. pii: S2211-1247(15)00065-0. doi: 10.1016/j.celrep.2015.01.040. [Epub ahead of print]

SapC-DOPS Nanovesicles as Targeted Therapy for Lung Cancer. Zhao S1, Chu Z2, Blanco VM3, Nie Y4, Hou Y4, Qi X5. Mol Cancer Ther. 2015 Feb;14(2):491-8. doi: 10.1158/1535-7163.MCT-14-0661.

Macrophage and Cancer Cell Cross-talk via CCR2 and CX3CR1 Is a Fundamental Mechanism Driving Lung Cancer. Schmall A1, Al-Tamari HM, Herold S, et al. Am J Respir Crit Care Med. 2015 Feb 15;191(4):437-47. doi: 10.1164/rccm.201406-1137OC.

Metabolomic Markers of Altered Nucleotide Metabolism in Early Stage Adenocarcinoma. Wikoff W1, Grapov D1, Fahrmann J1, et al. Cancer Prev Res (Phila). 2015 Feb 5. pii: canprevres.0329.2014. [Epub ahead of print]



Distress and Patient-Centered Communication among Veterans with Incidental (Not Screen-Detected) Pulmonary Nodules. A Cohort Study. Slatore CG1, Golden SE, Ganzini L, Wiener RS, Au DH. Ann Am Thorac Soc. 2015 Feb;12(2):184-92. doi: 10.1513/AnnalsATS.201406-283OC.

Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial. Navani N1, Nankivell M2, Lawrence DR3, ET AL. Lancet Respir Med. 2015 Feb 3. pii: S2213-2600(15)00029-6. doi: 10.1016/S2213-2600(15)00029-6. [Epub ahead of print]

Personalizing annual lung cancer screening for patients with chronic obstructive pulmonary disease: A decision analysis. Lowry KP1, Gazelle GS, Gilmore ME, et al. Cancer. 2015 Feb 3. doi: 10.1002/cncr.29225. [Epub ahead

Adequacy of core needle biopsy specimens and fine-needle aspirates for molecular testing of lung adenocarcinomas. Schneider F1, Smith MA2, Lane MC2, Pantanowitz L2, Dacic S2, Ohori NP2. Am J Clin Pathol. 2015 Feb;143(2):193-200. doi: 10.1309/AJCPMY8UI7WSFSYY.

Feasibility and Accuracy of Molecular Testing in Specimens Obtained with Small Biopsy Forceps: Comparison with the Results of Surgical Specimens. Oki M1, Yatabe Y, Saka H, Kitagawa C, Kogure Y, Ichihara S, Moritani S. Respiration. 2015 Feb 11. [Epub ahead of print]

Immunostaining in Lung Cancer for the Clinician: Commonly Used Markers for Differentiating Primary and Metastatic Pulmonary Tumors. Carney JM1, Kraynie AM, Roggli VL. Ann Am Thorac Soc. 2015 Feb 20. [Epub ahead of print]

Improving Selection Criteria for Lung Cancer Screening: the Potential Role of Emphysema. Sanchez-Salcedo P1, Wilson DO, de-Torres JP, et al. Am J Respir Crit Care Med. 2015 Feb 10. [Epub ahead of print]



Influence of smoking on perioperative oxidative stress after pulmonary resection. Mizuno Y1, Iwata H, Yamamoto H, Miyamoto Y, Mitta S, Shirahashi K, Takemura H. Surg Today. 2015 Feb 21. [Epub ahead of print]

VATS Versus Open Surgery for Lung Cancer Resection: Moving Beyond the Incision. Cheng AM1, Wood DE1. J Natl Compr Canc Netw. 2015 Feb;13(2):166-70.

Does obesity affect the outcomes of pulmonary resections for lung cancer? A National Surgical Quality Improvement Program analysis. Mungo B1, Zogg CK2, Hooker CM1, et al. Surgery. 2015 Feb 6. pii: S0039-6060(14)00712-0. doi: 10.1016/j.surg.2014.10.016. [Epub ahead of print]

Telomere length and recurrence risk after curative resection in patients with early-stage non-small-cell lung cancer: a prospective cohort study. Kim ES1, Ye Y, Vaporciyan AA, Xing J, Huang M, Gu J, Roth JA, Lippman SM, Wu X. J Thorac Oncol. 2015 Feb;10(2):302-8. doi: 10.1097/ JTO.0000000000000398.


A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients. Dikopf A1, Wood K, Salgia R.

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Paz-Ares L1, Mezger J2, Ciuleanu TE3, et al. Lancet Oncol. 2015 Feb 17. pii: S1470-2045(15)70046-X. doi: 10.1016/S1470-2045(15)70046-X. [Epub ahead of print]

Pemetrexed Singlet versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-Small Cell Lung Cancer Patients with EGFR Mutations. Park S1, Keam B1, Kim SH2, et al. Cancer Res Treat. 2015 Feb 16. doi: 10.4143/crt.2014.244. [Epub ahead of print]

Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer. Spigel DR1, Patel JD, Reynolds CH, et al. J Thorac Oncol. 2015 Feb;10(2):353-9. doi: 10.1097/JTO.0000000000000277.

Randomized Phase II Study of Concurrent Versus Sequential Alternating Gefitinib and Chemotherapy in Previously Untreated Non-small Cell Lung Cancer with Sensitive EGFR Mutations: NEJ005/TCOG0902. Sugawara S1, Oizumi S2, Minato K3, et al. Ann Oncol. 2015 Feb 10. pii: mdv063. [Epub ahead of print]

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Rizvi NA1, Mazières J2, Planchard D3, et al. Lancet Oncol. 2015 Feb 19. pii: S1470-2045(15)70054-9. doi: 10.1016/S1470-2045(15)70054-9. [Epub ahead of print]


Quantifying the impact of respiratory-gated 4D CT acquisition on thoracic image quality: A digital phantom study. Bernatowicz K1, Keall P2, Mishra P3, Knopf A1, Lomax A1, Kipritidis J2. Med Phys. 2015 Jan;42(1):324. doi: 10.1118/1.4903936.

Hippocampus-Sparing Whole-Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases From Lung Adenocarcinoma: Early Response and Dosimetric Evaluation. Kim KH1, Cho BC2, Lee CG1, et al. Technol Cancer Res Treat. 2015 Jan 18. pii: 1533034614566993. [Epub ahead of print]

Surrogate-driven deformable motion model for organ motion tracking in particle radiation therapy. Fassi A1, Seregni M, Riboldi M, et al. Phys Med Biol. 2015 Jan 23;60(4):1565-1582. [Epub ahead of print]

Intraoperative radiotherapy to treat newly diagnosed solitary brain metastasis: initial experience and long-term outcomes. Weil RJ1, Mavinkurve GG, Chao ST, Vogelbaum MA, Suh JH, Kolar M, Toms SA. J Neurosurg. 2015 Jan 23:1-8. [Epub ahead of print]

Luteolin acts as a radiosensitizer in non small cell lung cancer cells by enhancing apoptotic cell death through activation of a p38/ROS/caspase cascade. Cho HJ1, Ahn KC1, Choi JY1, et al. Int J Oncol. 2015 Mar;46(3):1149-58. doi: 10.3892/ijo.2015.2831. Epub 2015 Jan 9.

Ga-68 MAA Perfusion 4D-PET/CT Scanning Allows for Functional Lung Avoidance Using Conformal Radiation Therapy Planning. Siva S1, Devereux T2, Ball DL3, et al. Technol Cancer Res Treat. 2015 Jan 9. pii: 1533034614565534. [Epub ahead of print]

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Bradley JD1, Paulus R2, Komaki R3, et al. Lancet Oncol. 2015 Jan 15. pii: S1470-2045(14)71207-0. doi:

Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer. Dai Y1, Wei Q1, Schwager C1, et al. Radiother Oncol. 2015 Jan 12. pii: S0167-8140(14)00590-8. doi: 10.1016/j.radonc.2014.12.009. [Epub ahead of print]



Difference in Benefit of Chemotherapy Between Small Cell Lung Cancer Patients with Interstitial Pneumonia and Patients with Non-small Cell Lung Cancer. Kashiwabara K1, Semba H2, Fujii S2, Tsumura S2, Aoki R2. Anticancer Res. 2015 Feb;35(2):1065-71.

Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base. Combs SE1, Hancock JG, Boffa DJ, Decker RH, Detterbeck FC, Kim AW. J Thorac Oncol. 2015 Feb;10(2):316-23. doi: 10.1097/JTO.0000000000000402.

Randomized Phase II-III Study of Bevacizumab in Combination with Chemotherapy in Previously Untreated Extensive Small-Cell Lung Cancer: Results from the IFCT-0802 Trial. Pujol JL, Lavole A, Quoix E, et al. Ann Oncol. 2015 Feb 16. pii: mdv065. [Epub ahead of print]

Outcomes of small cell lung cancer patients treated with Cisplatin-Etoposide versus Carboplatin-Etoposide. Karam I1, Jiang SY, Khaira M, Lee CW, Schellenberg D. Am J Clin Oncol. 2015 Feb;38(1):51-4. doi: 10.1097/COC.0b013e31828aab2a.

Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer. Wakuda K1, Kenmotsu H, Naito T, et al. Am J Clin Oncol. 2015 Feb;38(1):28-32. doi: 10.1097/COC.0b013e318286907b.

MicroRNA-138 Regulates DNA Damage Response in Small Cell Lung Cancer Cells by Directly Targeting H2AX. Yang H1, Luo J, Liu Z, Zhou R, Luo H. Cancer Invest. 2015 Feb 20. [Epub ahead of print]


Challenges in assessing spiritual distress in survivors of cancer. Skalla K1, Ferrell B2. Clin J Oncol Nurs. 2015 Feb 1;19(1):99-104. doi: 10.1188/15.CJON.99-104.

Incongruent perceptions of pain and physical function among families living with lung cancer. Miller LM1, Lyons KS, Bennett JA. Support Care Cancer. 2015 Feb 12. [Epub ahead of print]

Survival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale. O’Mahony S1, Nathan S2, Mohajer R3, et al. Am J Hosp Palliat Care. 2015 Feb 10. pii: 1049909115570707. [Epub ahead of print]

Clinical features and survival of lung cancer patients with pleural effusions. Porcel JM1, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Respirology. 2015 Feb 23. doi: 10.1111/resp.12496. [Epub ahead of print]

The role of families in decisions regarding cancer treatments. Hobbs GS1, Landrum MB, Arora NK, et al. Cancer. 2015 Feb 23. doi: 10.1002/cncr.29064. [Epub ahead of print]

The association between fatalistic beliefs and late stage at diagnosis of lung and colorectal cancer. Lyratzopoulos G1, Liu MP2, Abel GA3, Wardle J4, Keating NL2. Cancer Epidemiol Biomarkers Prev. 2015 Feb 3. pii: cebp.0969.2014. [Epub ahead of print]

When do we need to care about the caregiver? Supportive care needs, anxiety, and depression among informal caregivers of patients with cancer and cancer survivors. Sklenarova H1, Krümpelmann A, Haun MW, et al. Cancer. 2015 Feb 11. doi: 10.1002/cncr.29223. [Epub ahead of print]


6-Shogaol, an Active Constituent of Dietary Ginger, Impairs Cancer Development and Lung Metastasis by Inhibiting the Secretion of CC-Chemokine Ligand 2 (CCL2) in Tumor-Associated Dendritic Cells. Hsu YL1, Hung JY, Tsai YM, Tsai EM, Huang MS, Hou MF, Kuo PL. J Agric Food Chem. 2015 Feb 18;63(6):1730-8. doi: 10.1021/jf504934m. Epub 2015 Feb 9.

Effect of Tai Chi on mononuclear cell functions in patients with non-small cell lung cancer. Liu J, Chen P, Wang R, Yuan Y, Wang X, Li C. BMC Complement Altern Med. 2015 Feb 5;15(1):3. [Epub ahead of print]

Cochinchina momordica seed suppresses proliferation and metastasis in human lung cancer cells by regulating multiple molecular targets. Shen Y1, Meng L, Sun H, Zhu Y, Liu H. Am J Chin Med. 2015;43(1):149-66. doi: 10.1142/S0192415X1550010X. Epub 2015 Feb 4.



Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Rangachari D1, Yamaguchi N1, VanderLaan PA2, et al. Lung Cancer. 2015 Feb 4. pii: S0169-5002(15)00081-1. doi: 10.1016/j.lungcan.2015.01.020. [Epub ahead of print]

Innovative Clinical Trials: The LUNG-MAP Study. Steuer CE1, Papadimitrakopoulou V, Herbst RS, et al. Clin Pharmacol Ther. 2015 Feb 10. doi: 10.1002/cpt.88. [Epub ahead of print]

Exposure-response relationships for select cancer and non-cancer health outcomes in a cohort of US firefighters from San Francisco, Chicago and Philadelphia (1950-2009). Daniels RD1, Bertke S1, Dahm MM1, et al. Occup Environ Med. 2015 Feb 11. pii: oemed-2014-102671. doi: 10.1136/oemed-2014-102671. [Epub ahead of print]

The past, present, and future of cancer incidence in the United States: 1975 through 2020. Weir HK1, Thompson TD, Soman A, Møller B, Leadbetter S. Cancer. 2015 Feb 3. doi: 10.1002/cncr.29258. [Epub ahead of print]

Does lung cancer attract greater stigma than other cancer types? Marlow LA1, Waller J2, Wardle J2. Lung Cancer. 2015 Feb 7. pii: S0169-5002(15)00086-0. doi: 10.1016/j.lungcan.2015.01.024. [Epub ahead of print]

Disparities in treatment of patients with inoperable stage I non-small cell lung cancer: a population-based analysis. Koshy M1, Malik R, Spiotto M, Mahmood U, Weichselbaum R, Sher D. J Thorac Oncol. 2015 Feb;10(2):264-71. doi: 10.1097/JTO.0000000000000418.

Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Herbst RS1, Gandara DR2, Hirsch FR3, et al. Clin Cancer Res. 2015 Feb 13. pii: clincanres.3473.2014. [Epub ahead of print]

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)